Report cover image

Global Osteoarthritis Drugs Market Growth, Size, Trends Analysis - By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Jul 11, 2025
Length 222 Pages
SKU # SPER20337453

Description

Global Osteoarthritis Drugs Market Introduction and Overview

According to SPER market research, ‘Global Osteoarthritis Drugs Market Size- By Drug Type, By Route of Administration, By Anatomy, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Osteoarthritis Drugs Market is predicted to reach 18.98 billion by 2034 with a CAGR of 7.13%.

Osteoarthritis therapeutics are medical treatments and interventions designed to control and alleviate the symptoms of osteoarthritis, a degenerative joint condition characterised by cartilage and bone breakdown. Analgesics, nonsteroidal anti-inflammatory medications (NSAIDs), corticosteroids, and disease-modifying osteoarthritis medicines (DMOADs) are among the options. Physical therapy, lifestyle adjustments, and surgical treatments such as joint replacement are all available as treatment alternatives.

Restraints:Excessive consumption of osteoarthritis medicines, such as non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, can result in side effects such as cardiovascular risks, gastrointestinal problems, and kidney concerns. Long-term use of these pharmaceuticals may result in a variety of health problems, posing challenges for both users and manufacturers.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered
By Connectivity, By Mounting

Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered
Canadian Solar, CHINT Group, First Solar, JA SOLAR Technology Co., Ltd, JinkoSolar, LG Electronics, Shunfeng International Clean Energy Co., Ltd, The Solaria Corporation, Trina Solar.

Global Osteoarthritis Drugs Market Segmentation:


By Drug Type: Based on the Drug Type, Global Osteoarthritis Drugs Market is segmented as; Visco Supplementation Agents, NSAIDs, Analgesics, Corticosteroids.

By Route of Administration: Based on the Route of Administration, Global Osteoarthritis Drugs Market is segmented as; Oral, Parenteral, Topical.

By Anatomy: Based on the Anatomy, Global Osteoarthritis Drugs Market is segmented as; Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, Other Anatomies.

By Distribution Channel: Based on the Distribution Channel, Global Osteoarthritis Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

222 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Osteoarthritis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Osteoarthritis Drugs Market
7. Global Osteoarthritis Drugs Market, By Drug Type (USD Million) 2021-2034
7.1. Visco Supplementation Agents
7.2. Nonsteroidal Anti-Inflammatory Drugs
7.2.1. Naproxen
7.2.2. Aspirin
7.2.3. Diclofenac
7.2.4. Ibuprofen
7.2.5. Celecoxib
7.2.6. Meloxicam
7.2.7. Piroxicam
7.2.8. Ketoprofen
7.2.9. Other NSAIDs
7.3. Analgesics
7.3.1. Duloxetine
7.3.2. Acetaminophen
7.4. Corticosteroids
7.5. Other Drug Types
8. Global Osteoarthritis Drugs Market, By Route of Administration (USD Million) 2021-2034
8.1. Oral
8.2. Parenteral
8.3. Topical
9. Global Osteoarthritis Drugs Market, By Anatomy (USD Million) 2021-2034
9.1. Ankle Osteoarthritis
9.2. Hip Osteoarthritis
9.3. Knee Osteoarthritis
9.4. Shoulder Osteoarthritis
9.5. Other Anatomies
10. Global Osteoarthritis Drugs Market, By Distribution Channel (USD Million) 2021-2034
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacy
11. Global Osteoarthritis Drugs Market, (USD Million) 2021-2034
11.1. Global Osteoarthritis Drugs Market Size and Market Share
12. Global Osteoarthritis Drugs Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Anika Therapeutics
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Assertio Holdings, Inc
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Bayer AG
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Bioventus
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Ferring Pharmaceuticals Inc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. GlaxoSmithKline plc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Novartis AG
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Pacira Pharmaceuticals, Inc
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Pfizer Inc
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Sanofi SA
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us